Disparities in the Use of SGLT2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Adults With CKD in the United States
Main Authors: | Susanne B. Nicholas, Radica Z. Alicic, Jenny Shen |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-01-01
|
Series: | Kidney Medicine |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2590059522002230 |
Similar Items
-
Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United StatesPlain-Language Summary
by: Julie Z. Zhao, et al.
Published: (2023-01-01) -
Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United StatesPlain-Language Summary
by: Julie Z. Zhao, et al.
Published: (2022-08-01) -
Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
by: Richard J. MacIsaac, et al.
Published: (2024-10-01) -
Nephroprotective potential of glucagon-like peptide-1 receptor agonists
by: Minara S. Shamkhalova, et al.
Published: (2020-04-01) -
Glucagon-like peptide-1 receptor agonists in neoplastic diseases
by: Lisan Ji, et al.
Published: (2024-09-01)